Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRE Stock Forecast 2026-2027
$17.98
Current Price
$303.40M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRE Price Targets
+100.2%
To High Target of $36.00
+66.9%
To Median Target of $30.00
+61.3%
To Low Target of $29.00
PRE Price Momentum
+1.3%
1 Week Change
-8.4%
1 Month Change
+299.6%
1 Year Change
+14.2%
Year-to-Date Change
-23.9%
From 52W High of $23.63
+333.3%
From 52W Low of $4.15
📊 TOP ANALYST CALLS
Did PRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prenetics is one of their latest high-conviction picks.
Latest PRE Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PRE has a bullish consensus with a median price target of $30.00 (ranging from $29.00 to $36.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $17.98, the median forecast implies a 66.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Ryan Meyers at Lake Street, suggesting a 61.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRE Analyst Ratings
2
Buy
0
Hold
0
Sell
PRE Price Target Range
Low
$29.00
Average
$30.00
High
$36.00
Current: $17.98
Latest PRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 16, 2026 | Lake Street | Ryan Meyers | Buy | Initiates | $29.00 |
| Oct 29, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $32.00 |
| Jan 16, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Dec 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $9.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $4.00 |
| Sep 19, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $4.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jan 18, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $7.00 |
| Jul 28, 2015 | Barclays | Overweight | Maintains | $140.00 | |
| Jul 9, 2015 | Deutsche Bank | Hold | Maintains | $6.10 | |
| Jun 18, 2015 | Keefe, Bruyette & Woods | Market Perform | Maintains | $140.00 | |
| May 13, 2015 | BMO Capital | Market Perform | Maintains | $137.50 | |
| May 6, 2015 | Deutsche Bank | Hold | Maintains | $6.50 | |
| Apr 22, 2015 | UBS | Neutral | Downgrade | $N/A | |
| Apr 20, 2015 | Deutsche Bank | Hold | Maintains | $130.00 | |
| Apr 17, 2015 | BMO Capital | Market Perform | Downgrade | $130.00 | |
| Mar 26, 2015 | BMO Capital | Outperform | Upgrade | $122.00 | |
| Feb 5, 2015 | JMP Securities | Market Perform | Downgrade | $N/A | |
| Jan 20, 2015 | Deutsche Bank | Hold | Maintains | $6.10 |
Prenetics Global Limited (PRE) Competitors
The following stocks are similar to Prenetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prenetics Global Limited (PRE) Financial Data
Prenetics Global Limited has a market capitalization of $303.40M with a P/E ratio of 1.1x. The company generates $92.39M in trailing twelve-month revenue with a -63.1% profit margin.
Revenue growth is +248.6% quarter-over-quarter, while maintaining an operating margin of -33.3% and return on equity of -31.8%.
Valuation Metrics
Market Cap
$303.40M
Enterprise Value
$214.22M
P/E Ratio
1.1x
PEG Ratio
0.0x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+248.6%
Gross Margin
+59.5%
Operating Margin
-33.3%
Net Margin
-63.1%
EPS Growth
+202.8%
Financial Health
Cash/Price Ratio
+25.4%
Current Ratio
3.0x
Debt/Equity
1.0x
ROE
-31.8%
ROA
-11.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prenetics Global Limited (PRE) Business Model
About Prenetics Global Limited
What They Do
Health sciences company specializing in genomic testing.
Business Model
Prenetics Global Limited operates through three primary segments: Prevention via CircleDNA's direct-to-consumer genetic testing, Diagnostics through ACT Genomics' precision oncology services, and Consumer Health with wellness products like IM8 Health. The company generates revenue by selling genetic tests, providing diagnostic services, and distributing health supplements and nutrition products globally.
Additional Information
Headquartered in Hong Kong, Prenetics is notable for being the first Asia-based firm to gain FDA clearance for comprehensive genomic profiling of solid tumors. Its products are distributed through various channels including retail partnerships and online platforms, catering to both individual consumers and healthcare professionals across multiple international markets.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
285
CEO
Mr. Sheng Wu Yeung
Country
Hong Kong
IPO Year
2022
Website
www.prenetics.comPrenetics Global Limited (PRE) Latest News & Analysis
Latest News
Quick Summary
Prenetics Global Limited (PRE) is rated a buy, with potential upsides of 15% near-term and 60% over 24 months, supported by revenue growth, strategic focus, and strong liquidity with $100M cash.
Why It Matters
Prenetics Global Limited's strong growth projections, strategic focus, and solid liquidity position enhance its attractiveness, signaling potential for significant returns with reduced risk.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) has announced a strategic partnership with Superpower, enhancing its health offerings by integrating clinical-grade supplementation with blood diagnostics.
Why It Matters
Prenetics' partnership with Superpower enhances its product offering by integrating diagnostics with supplements, potentially increasing market appeal and revenue growth, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited (PRE) held its Q4 2025 earnings call, discussing financial performance and future outlook. Further details can be accessed in the full transcript.
Why It Matters
Prenetics Global Limited's Q4 2025 earnings reveal financial health, growth potential, and strategic direction, impacting stock valuation and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
2 months ago
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) appointed Dr. Darshan Shah as an independent director, effective February 16, 2026, enhancing its board with expertise in healthspan optimization.
Why It Matters
The appointment of Dr. Darshan Shah enhances Prenetics' leadership with expertise that may drive growth in healthspan optimization, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY
2 months ago
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) reported its financial results for Q4 and the full year ended December 31, 2025. Further details were not provided in the excerpt.
Why It Matters
Prenetics' financial results can influence stock performance, reflecting company growth, investor sentiment, and market positioning in the health sciences sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited sold its 35% stake in Insighta to Tencent for $70 million, enhancing its cash resources and supporting the global expansion of its IM8 brand. Q4 and 2025 results on Feb 18, 2026.
Why It Matters
Prenetics' sale of its Insighta stake boosts cash reserves, enhances financial stability, and supports IM8's global expansion, signaling growth potential that can attract investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRE Stock
What is Prenetics Global Limited's (PRE) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Prenetics Global Limited (PRE) has a median price target of $30.00. The highest price target is $36.00 and the lowest is $29.00.
Is PRE stock a good investment in 2026?
According to current analyst ratings, PRE has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRE stock?
Wall Street analysts predict PRE stock could reach $30.00 in the next 12 months. This represents a 66.9% increase from the current price of $17.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prenetics Global Limited's business model?
Prenetics Global Limited operates through three primary segments: Prevention via CircleDNA's direct-to-consumer genetic testing, Diagnostics through ACT Genomics' precision oncology services, and Consumer Health with wellness products like IM8 Health. The company generates revenue by selling genetic tests, providing diagnostic services, and distributing health supplements and nutrition products globally.
What is the highest forecasted price for PRE Prenetics Global Limited?
The highest price target for PRE is $36.00 from at , which represents a 100.2% increase from the current price of $17.98.
What is the lowest forecasted price for PRE Prenetics Global Limited?
The lowest price target for PRE is $29.00 from Ryan Meyers at Lake Street, which represents a 61.3% increase from the current price of $17.98.
What is the overall PRE consensus from analysts for Prenetics Global Limited?
The overall analyst consensus for PRE is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PRE stock price projections?
Stock price projections, including those for Prenetics Global Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 12:16 PM UTC